Asparagus officinalis combined with paclitaxel exhibited synergistic anti-tumor activity in paclitaxel-sensitive and -resistant ovarian cancer cells.
Asparagus officinalis
Cytotoxicity
DNA damage
Ovarian cancer
Paclitaxel resistance
Synergy
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
12
07
2022
accepted:
08
08
2022
medline:
5
7
2023
pubmed:
26
8
2022
entrez:
25
8
2022
Statut:
ppublish
Résumé
Although paclitaxel is a promising first-line chemotherapeutic drug for ovarian cancer, acquired resistance to paclitaxel is one of the leading causes of treatment failure, limiting its clinical application. Asparagus officinalis has been shown to have anti-tumorigenic effects on cell growth, apoptosis, cellular stress and invasion of various types of cancer cells and has also been shown to synergize with paclitaxel to inhibit cell proliferation in ovarian cancer. Human ovarian cancer cell lines MES and its PTX-resistant counterpart MES-TP cell lines were used and were treated with Asparagus officinalis and paclitaxel alone as well as in combination. Cell proliferation, cellular stress, invasion and DMA damage were investigated and the synergistic effect of a combined therapy analyzed. In this study, we found that Asparagus officinalis combined with low-dose paclitaxel synergistically inhibited cell proliferation, induced cellular stress and apoptosis and reduced cell invasion in paclitaxel-sensitive and -resistant ovarian cancer cell lines. The combined treatment effects were dependent on DNA damage pathways and suppressing microtubule dynamics, and the AKT/mTOR pathway and microtubule-associated proteins regulated the inhibitory effect through different mechanisms in paclitaxel-sensitive and -resistant cells. These findings suggest that the combination of Asparagus officinalis and paclitaxel have potential clinical implications for development as a novel ovarian cancer treatment strategy.
Identifiants
pubmed: 36006482
doi: 10.1007/s00432-022-04276-8
pii: 10.1007/s00432-022-04276-8
pmc: PMC10314877
doi:
Substances chimiques
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3871-3883Subventions
Organisme : Beijing health system high-level health personnel training program fund
ID : 2014-3-073
Organisme : National Institute for Health Care Management Foundation
ID : R37CA226969
Informations de copyright
© 2022. The Author(s).
Références
J Sci Food Agric. 2013 Apr;93(6):1492-8
pubmed: 23450726
Lancet. 2014 Oct 11;384(9951):1376-88
pubmed: 24767708
Cancer Genomics Proteomics. 2021 Sep-Oct;18(5):645-659
pubmed: 34479917
Phytother Res. 2018 Jul;32(7):1297-1303
pubmed: 29532545
Front Endocrinol (Lausanne). 2021 Nov 17;12:772349
pubmed: 34867818
J Agric Food Chem. 2018 Oct 17;66(41):10703-10711
pubmed: 30251849
Am J Cancer Res. 2018 Jul 01;8(7):1317-1331
pubmed: 30094104
Med Res Rev. 2016 Mar;36(2):300-12
pubmed: 26332739
Oncogene. 2003 Oct 20;22(47):7280-95
pubmed: 14576838
Front Oncol. 2021 Jul 14;11:688461
pubmed: 34336674
Oncol Lett. 2020 Sep;20(3):2689-2700
pubmed: 32782585
Cell Cycle. 2014;13(22):3590-601
pubmed: 25483095
Med Princ Pract. 2016;25 Suppl 2:41-59
pubmed: 26679767
Adv Colloid Interface Sci. 2016 Jun;232:9-16
pubmed: 26684364
Br J Cancer. 2014 Apr 15;110(8):1958-67
pubmed: 24642627
J Agric Food Chem. 2020 Jan 8;68(1):213-224
pubmed: 31861958
Br J Pharmacol. 2020 Mar;177(6):1409-1423
pubmed: 31368509
Br J Cancer. 2016 Aug 9;115(4):431-41
pubmed: 27415012
Int J Mol Sci. 2020 Dec 27;22(1):
pubmed: 33375416
Biochem Biophys Res Commun. 2001 Nov 23;289(1):120-4
pubmed: 11708787
Apoptosis. 2013 Mar;18(3):347-60
pubmed: 23271172
Tumour Biol. 2014 Apr;35(4):3517-24
pubmed: 24310501
Drug Resist Updat. 2021 Jan;54:100742
pubmed: 33429249
Redox Biol. 2019 Jul;25:101084
pubmed: 30612957
Ann Oncol. 1997 Aug;8(8):803-6
pubmed: 9332691
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Front Pharmacol. 2021 Oct 27;12:738914
pubmed: 34776959
Int J Oncol. 2007 Aug;31(2):277-83
pubmed: 17611683
Cancer Cell. 2010 Aug 9;18(2):109-21
pubmed: 20708153
Biomed Pharmacother. 2021 Sep;141:111824
pubmed: 34175815
J Natl Cancer Inst. 2010 Oct 20;102(20):1547-56
pubmed: 20937992
Drug Resist Updat. 2021 Mar;55:100754
pubmed: 33691261
Cells. 2022 Jul 15;11(14):
pubmed: 35883653
J Exp Clin Cancer Res. 2019 Jun 14;38(1):258
pubmed: 31200779
Molecules. 2021 Oct 21;26(21):
pubmed: 34770777
Cancers (Basel). 2021 Dec 12;13(24):
pubmed: 34944858
Cancers (Basel). 2020 Nov 10;12(11):
pubmed: 33182737
Oncol Lett. 2020 Nov;20(5):141
pubmed: 32934709
Mol Oncol. 2014 Oct;8(7):1231-9
pubmed: 24816187
Anticancer Agents Med Chem. 2021;21(6):668-678
pubmed: 32900355
Expert Opin Drug Metab Toxicol. 2014 Dec;10(12):1677-90
pubmed: 25339439
Biochem Pharmacol. 2021 Aug;190:114598
pubmed: 33979647
Cancer Lett. 2012 Dec 30;326(2):176-82
pubmed: 22902993
Clin Cancer Res. 1998 Feb;4(2):389-98
pubmed: 9516927
Pharmacol Res Perspect. 2015 Jun;3(3):e00149
pubmed: 26171228
Food Chem Toxicol. 2021 Apr;150:112036
pubmed: 33561516
Biomark Cancer. 2019 Jul 05;11:1179299X19860815
pubmed: 31308780
Molecules. 2022 Jul 26;27(15):
pubmed: 35897965
Cancer Chemother Pharmacol. 2017 Nov;80(5):909-917
pubmed: 28741098
Front Oncol. 2022 Mar 17;12:789450
pubmed: 35372029
Acta Pharmacol Sin. 2017 Jun;38(6):859-873
pubmed: 28260803
Biomolecules. 2019 Nov 21;9(12):
pubmed: 31766399